Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1965 1
1966 2
1967 1
1968 1
1969 6
1970 1
1971 2
1973 1
1974 2
1979 1
1980 1
1981 2
1984 1
1985 3
1986 2
1987 4
1988 2
1989 3
1990 2
1991 4
1992 2
1993 6
1994 6
1995 4
1996 3
1997 1
1999 5
2000 11
2001 10
2002 17
2003 11
2004 14
2005 10
2006 17
2007 13
2008 13
2009 13
2010 15
2011 15
2012 23
2013 19
2014 20
2015 25
2016 20
2017 29
2018 34
2019 35
2020 39
2021 53
2022 43
2023 43
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

569 results

Results by year

Filters applied: . Clear all
Page 1
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Saji H, et al. Among authors: nakajima r. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. Lancet. 2022. PMID: 35461558 Clinical Trial.
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Aokage K, et al. Among authors: nakajima r. Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6. Lancet Respir Med. 2023. PMID: 36893780 Clinical Trial.
Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids.
Kastenschmidt JM, Sureshchandra S, Jain A, Hernandez-Davies JE, de Assis R, Wagoner ZW, Sorn AM, Mitul MT, Benchorin AI, Levendosky E, Ahuja G, Zhong Q, Trask D, Boeckmann J, Nakajima R, Jasinskas A, Saligrama N, Davies DH, Wagar LE. Kastenschmidt JM, et al. Among authors: nakajima r. Immunity. 2023 Aug 8;56(8):1910-1926.e7. doi: 10.1016/j.immuni.2023.06.019. Epub 2023 Jul 20. Immunity. 2023. PMID: 37478854 Free PMC article.
[Anti-doping and Pharmaceutical Sciences].
Shimba S, Nakajima R. Shimba S, et al. Among authors: nakajima r. Yakugaku Zasshi. 2022;142(2):101-102. doi: 10.1248/yakushi.21-00169-F. Yakugaku Zasshi. 2022. PMID: 35110443 Free article. Japanese. No abstract available.
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial.
Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, Nakajima R, Tsuboi M, Nakamura S, Nakamura K, Mitsudomi T, Asamura H; West Japan Oncology Group; Japan Clinical Oncology Group. Suzuki K, et al. Among authors: nakajima r. J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907. doi: 10.1016/j.jtcvs.2019.03.090. Epub 2019 Apr 9. J Thorac Cardiovasc Surg. 2019. PMID: 31078312 Free article. Clinical Trial.
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors.
Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, Shimomura A, Ikezawa H, Nomoto M, Furuuchi K, Nakajima R, Miura T, Yamamoto N. Shimizu T, et al. Among authors: nakajima r. Clin Cancer Res. 2021 Jul 15;27(14):3905-3915. doi: 10.1158/1078-0432.CCR-20-4740. Epub 2021 Apr 29. Clin Cancer Res. 2021. PMID: 33926914 Clinical Trial.
B chromosomes: from cytogenetics to systems biology.
Valente GT, Nakajima RT, Fantinatti BE, Marques DF, Almeida RO, Simões RP, Martins C. Valente GT, et al. Among authors: nakajima rt. Chromosoma. 2017 Feb;126(1):73-81. doi: 10.1007/s00412-016-0613-6. Epub 2016 Aug 24. Chromosoma. 2017. PMID: 27558128 Review.
11C-methionine PET/CT findings in benign brain disease.
Nakajima R, Kimura K, Abe K, Sakai S. Nakajima R, et al. Jpn J Radiol. 2017 Jun;35(6):279-288. doi: 10.1007/s11604-017-0638-7. Epub 2017 Apr 18. Jpn J Radiol. 2017. PMID: 28421396 Review.
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.
Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Sekino Y, Tsutani Y, Nakajima R, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Nakamura K, Fukuda H, Watanabe SI; Japan Clinical Oncology Group; West Japan Oncology Group. Hattori A, et al. Among authors: nakajima r. Lancet Respir Med. 2024 Feb;12(2):105-116. doi: 10.1016/S2213-2600(23)00382-X. Epub 2024 Jan 3. Lancet Respir Med. 2024. PMID: 38184010 Clinical Trial.
569 results